The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Treatment Individualisation by EBV Stratification in Nasopharyngeal Carcinoma: a Prospective Observational Study
Official Title: Treatment Individualisation by EBV Stratification in Nasopharyngeal Carcinoma: a Prospective Observational Study
Study ID: NCT05517135
Brief Summary: This is a prospective platform study that will investigate the outcomes of patients with locoregionally-advanced nasopharyngeal carcinoma (LA-NPC) or recurrent-metastatic nasopharyngeal carcinoma (RM-NPC) who are assigned to treatment arms of different chemotherapy sequencing and intensity based on their pre- and on-treatment plasma EBV DNA results.
Detailed Description: The primary objectives of this platform are: (1) to prospectively validate the prognostic potential of an EBV DNA-based risk-stratification strategy of patients with LA- and RM-NPC; and (2) to test if treatment individualization strategies based on pre- and on-treatment plasma EBV DNA will improve survival outcomes. Primary study end-point is 2-year disease-free survival (DFS).
Minimum Age: 21 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
National Cancer Centre Singapore, Singapore, , Singapore
Name: Melvin Lee Kiang Chua, MBBS, FRCR, PhD, FAMS
Affiliation: National Cancer Centre, Singapore
Role: PRINCIPAL_INVESTIGATOR